Correction to:The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure by Santema, Bernadet T. et al.
                                                                    
University of Dundee
Correction to
Santema, Bernadet T.; Chan, Michelle M. Y.; Tromp, Jasper; Dokter, Martin; van der Wal,
Haye H.; Emmens, Johanna E.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Santema, B. T., Chan, M. M. Y., Tromp, J., Dokter, M., van der Wal, H. H., Emmens, J. E., Takens, J., Samani,
N. J., Ng, L. L., Lang, C. C., van der Meer, P., Ter Maaten, J. M., Damman, K., Dickstein, K., Cleland, J. G.,
Zannad, F., Anker, S. D., Metra, M., van der Harst, P., ... Voors, A. A. (2020). Correction to: The influence of
atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in
Cardiology . https://doi.org/10.1007/s00392-020-01762-2
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
Vol.:(0123456789) 
Clinical Research in Cardiology 
https://doi.org/10.1007/s00392-020-01762-2
CORRECTION
Correction to: The influence of atrial fibrillation on the levels 
of NT‑proBNP versus GDF‑15 in patients with heart failure
Bernadet T. Santema1 · Michelle M. Y. Chan2 · Jasper Tromp1,2 · Martin Dokter1 · Haye H. van der Wal1 · 
Johanna E. Emmens1 · Janny Takens1 · Nilesh J. Samani3,4 · Leong L. Ng3,4 · Chim C. Lang5 · Peter van der Meer1 · 
Jozine M. ter Maaten1 · Kevin Damman1 · Kenneth Dickstein6,7 · John G. Cleland8,9 · Faiez Zannad10 · 
Stefan D. Anker11 · Marco Metra12 · Pim van der Harst1 · Rudolf A. de Boer1 · Dirk J. van Veldhuisen1 · 
Michiel Rienstra1 · Carolyn S. P. Lam1,2 · Adriaan A. Voors1 
 
© The Author(s) 2020
Correction to:  
Clinical Research in Cardiology (2020) 109:331–338  
https ://doi.org/10.1007/s0039 2-019-01513 -y
The original version of this article unfortunately contained a 
mistake. Section “Results”, second paragraph, first sentence 
should read:
The plasma levels of NT-proBNP were significantly 
higher in patients who had AF at baseline, with a median 
of 3417 pg/mL (1897–6486), as compared with patients 
who were in SR at baseline; both those who had a history 
of AF (1788 pg/mL [682–3870], p < 0.001) and those who 
never had AF before (2231 pg/mL [902–5270], p < 0.001) 
(Table 1), also after multivariable adjustment (Table 2).
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
The original article can be found online at https ://doi.org/10.1007/
s0039 2-019-01513 -y.
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